MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% - Time to Sell?

Key Points

• Shares were trading down 4.3% to about $12.62 on Friday with just 208,023 shares changing hands (an 86% decline from average volume), and the stock sits below its 50‑day moving average ($12.79) and well under its 200‑day average ($32.83).
• Several firms sharply cut price targets while leaving mixed ratings—Guggenheim to $20, Wedbush to $18, RBC to $10 and Goldman to $7—leaving a MarketBeat consensus of “Hold” and an average target of $30.25.
• The company missed quarterly EPS (‑$1.10 vs. ‑$0.89 expected) and insiders have been selling heavily (402,908 shares worth about $6.0M over the last 90 days, including two 130k‑share sales at $15.08 each).

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) traded down 4.3% during mid-day trading on Friday . The stock traded as low as $12.42 and last traded at $12.6150. 208,023 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 1,500,665 shares. The stock had previously closed at $13.18.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Guggenheim reduced their target price on MoonLake Immunotherapeutics from $80.00 to $20.00 and set a "buy" rating on the stock in a report on Tuesday, September 30th. Wedbush cut their price objective on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an "outperform" rating for the company in a research report on Tuesday, September 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $10.00 price target (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a report on Monday, September 29th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $7.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 1st. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of "Hold" and an average target price of $30.25.

MoonLake Immunotherapeutics Stock Performance

The company has a 50-day moving average price of $12.79 and a two-hundred day moving average price of $32.83. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $800.95 million, a P/E ratio of -3.75 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period in the previous year, the firm posted ($0.56) earnings per share. On average, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the sale, the insider owned 72,908 shares in the company, valued at approximately $1,099,452.64. This trade represents a 64.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the chief executive officer directly owned 2,948,577 shares of the company's stock, valued at $44,464,541.16. The trade was a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 402,908 shares of company stock valued at $5,987,162 over the last 90 days. Company insiders own 12.02% of the company's stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter valued at $94,000. Cubist Systematic Strategies LLC bought a new position in MoonLake Immunotherapeutics in the first quarter valued at $970,000. Advisors Asset Management Inc. raised its position in MoonLake Immunotherapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock valued at $157,000 after purchasing an additional 1,803 shares in the last quarter. Granahan Investment Management LLC raised its position in MoonLake Immunotherapeutics by 4.2% during the first quarter. Granahan Investment Management LLC now owns 142,220 shares of the company's stock valued at $5,557,000 after purchasing an additional 5,782 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company's stock worth $13,453,000 after purchasing an additional 334,320 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.